Diabetes and Other Diseases
622 articles
Mary Fisher
The world “discovered” Mary Fisher on the evening of August 19, 1992, when she delivered a speech at the 1992 Republican Convention. It is ranked as one of the 100 greatest American speeches in the 20th Century. Since the steaming night in Houston, the world has come to know Mary as a gifted artist, a […]
Report Highlights Potential of TCR Therapy
Read about the potential of TCR therapy, a technique used with success for one pancreatic cancer patient in a groundbreaking immunotherapy clinical trial.
Large Phase III Global Trial Targets Cancer Metabolism
Dr. Philip Philip focuses on disrupting cancer cell metabolism with devimistat, now in a phase III global clinical trial.
Complementary Therapies—a Way to Gain Peace?
What techniques are other pancreatic cancer patients using to relieve symptoms and side effects, and cope with treatment? Learn more about the most popular complementary therapies.
When Certain Chemotherapy Drugs Are in Short Supply
It’s been all over the news–some chemotherapy drugs are in short supply. Dr. Allyson Ocean explains a doctor’s options in these situations.
Understanding How Super-Enhancers Rev Up Pancreatic Cancer Growth
Researcher Ronald Evans, Ph.D., and his team at the Salk Institute are focusing on how super-enhancers stimulate pancreatic cancer growth.
Study Reveals Molecular Differences in Young-Onset Pancreatic Cancer
There has been a notable increase in cases of young onset pancreatic cancer. Dr. Jashodeep Datta and team are exploring why this is happening.
Laboratory Study Shows Keto Diet May Enhance Chemotherapy
Dr. Joshua Rabinowitz’s initial study has found that a Keto diet may enhance the effects of chemotherapy and treatment for pancreatic cancer.
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Dr. Michael Pishvaian leads research into the possible role of PARP inhibitors in treating pancreatic cancer patients with certain genetic mutations.